Navigation Links
Pharmasset Reports Fiscal First Quarter 2011 Financial Results
Date:2/7/2011

8 in mid-2011

-- Bristol-Myers Squibb is anticipated to initiate a combination trial of PSI-7977 and BMY-790052 during the first half of 2011

-- Pharmasset plans to submit an IND for PSI-661 in the first quarter of 2011 and to initiate a phase 1 trial in the second quarter of 2011

-- Roche expects to initiate INFORM-SVR with RG7128 and RG7227 in the first quarter of 2011

-- Roche expects to initiate a Phase 2 study with RG7128 in HCV genotype 2/3 patients in the first half of 2011

-- Roche expects to initiate a Phase 3 program with RG7128 in 2011 and file in 2013

About PharmassetPharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis C virus (HCV). Our research and development efforts focus on nucleoside/tide analogs, a class of compounds which act as alternative substrates for the viral polymerase, thus inhibiting viral replication. We currently have three clinical-stage product candidates. RG7128, a cytosine nucleoside analog for chronic HCV infection, is in two Phase 2b clinical studies in combination with Pegasys® plus Copegus® and is also in the INFORM studies, the first series of studies designed to assess the potential of combinations of small molecules without Pegasys® and Copegus® to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage HCV candidates include PSI-7977, an unpartnered uracil nucleotide analog that has recently initiated dosing in two Phase 2b studies in patients with HCV genotypes 1, 2, or 3, and PSI-938, an unpartnered guanosine nucleotide analog which recently completed a 14-day monotherapy study and has recently initiated a 14-day combination study with PSI-7977. We also have in our pipeline an addition
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
5. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
6. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
9. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
10. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
11. Pharmasset Receives Notice of Allowance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... , March 31, 2015 MedSpring Urgent Care is pleased ... Dallas/Fort-Worth area of Upper Greenville. The center – ... Dallas location. Knox - ... by the surrounding community since opening last fall. Additional ... the Keller and Las Colinas neighborhoods this ...
(Date:3/31/2015)... -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ("Galmed"), ... and commercialization of a once-daily, oral therapy for ... today announced financial results for the 12 months ... 2014 Highlights: , Hosted a key opinion ... Rohit Loomba, MD, MHSc., who discussed the topic ...
(Date:3/31/2015)... TAMPA, Fla. , March 31, 2015  Oxis ... biotech cancer therapy development and commercialization, announced today Oxis ... of the trading of Oxis common shares on the ... the OTCQB under the symbol OXIS.   ... "As Oxis continues to move forward with its strategies ...
Breaking Medicine Technology:MedSpring Urgent Care Opens New Upper Greenville Location in Dallas 2Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 2Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 3Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 4Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 5Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 6Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 7Galmed Pharmaceuticals Reports Full Year 2014 Financial Results and Provides Business Update 8Oxis International Inc. Announces Request for Euronext Trading Suspension 2
(Date:3/31/2015)... March 31, 2015 Students, teachers, and ... for education in a drastically different way as current ... learning and training content is being delivered and received. ... by technology in an unprecedented way with education becoming ... Cumavoo, co-founder and CEO, My Mobile University , ...
(Date:3/31/2015)... Clinovo, a leading provider of ... , the premiere voice of Northern California’s Life ... companies. , BayBio brings together the collective ... and productive life science cluster, helping companies grow, ... most pressing challenges. , “We are thrilled ...
(Date:3/31/2015)... March 31, 2015 Dr. Russell Ashinoff is ... Reconstruction. He was recently quoted in an Asbury Park ... lymphatic issues, causing fluid retention and tissue swelling. Dr. ... relieve and / or improve lymphedema symptoms. , ... alleviate the symptoms of lymphedema. The goal is to ...
(Date:3/31/2015)... Dr. Uzma Parvez is having a busy start to ... Grounds Presentations at St. Michael’s Medical Center for attending staff ... The event was attended by a large gathering of students, ... from the Grand Rounds. It was said that it ... while. , Ahead, Dr. Parvez has been invited to ...
(Date:3/31/2015)... 2015 One of the most beautiful and awe-inspiring ... Mount Kilauea on the big island. The big island of ... can see molten lava slowly oozing at your feet in one ... , One place you would never expect to see a live ... of Mission, Texas -- until now. , Members of a local ...
Breaking Medicine News(10 mins):Health News:LTT Global Communications Launches First Asia Holistic Online Learning Platform 2Health News:LTT Global Communications Launches First Asia Holistic Online Learning Platform 3Health News:Clinovo Joins BayBio Membership Program, The Leading Life Science Association in Northern California 2Health News:The Physicians at Plastic Surgery Center Each Have Something to Celebrate This March 2Health News:The Physicians at Plastic Surgery Center Each Have Something to Celebrate This March 3Health News:The Physicians at Plastic Surgery Center Each Have Something to Celebrate This March 4Health News:NJ Top Docs Presents, Dr. Uzma Parvez of Total Pain Care 2Health News:Rare Volcano Constructed inside Gold’s Gym in Mission, Texas 2Health News:Rare Volcano Constructed inside Gold’s Gym in Mission, Texas 3
... the plant that attracts domestic cats like an irresistible ... blood-sucking flies that attack horses and cows, causing $2 ... the word from a report published in ACS, biweekly ... Junwei Zhu and colleagues note that stable flies not ...
... infected with HIV get pregnant more often and suffer pregnancy ... research led by Johns Hopkins investigators. A report ... from 181 patients with HIV, ages 13 to 24, treated ... the Feb. 2 issue of the Journal of the ...
... Johns Hopkins have found a better way to create ... properties of embryonic stem cellsfrom a small blood sample. ... Research , avoids creating DNA changes that could lead ... safer than ones made with previous technologies because they ...
... combination selectively crosses the tight barrier that protects the brain ... brain tumors, a research team led by scientists from The ... January issue of the Journal of Clinical Investigation . ... targeted particles guide payloads to image tumors, treat tumors, or ...
... teens and young women are more likely to get pregnant and ... HIV, a new study finds. Researchers from Johns Hopkins analyzed ... who had been treated at four hospitals over 12 years. More ... for a total of 96 pregnancies. The rate of premature ...
... TUESDAY, Feb. 1 (HealthDay News) -- End-of-life care facilities ... require less-skilled care on the part of the hospice, or ... Under the current Medicare reimbursement system -- which ... -- such patients would likely cost less to care for, ...
Cached Medicine News:Health News:Teens with HIV at high risk for pregnancy, complications 2Health News:Johns Hopkins researchers develop safer way to make induced pluripotent stem cells 2Health News:Targeted particle fools brain's guardian to reach tumors 2Health News:Targeted particle fools brain's guardian to reach tumors 3Health News:Targeted particle fools brain's guardian to reach tumors 4Health News:HIV Linked to Higher Pregnancy Rate in Young Women 2Health News:For-Profit Hospices May Prefer Certain Types of Patients: Study 2Health News:For-Profit Hospices May Prefer Certain Types of Patients: Study 3
Gerald forceps. Insulated....
Cushing forceps. Insulated....
Angled 60 degree blades 5.5 mm....
... Nystagmus when rotated at 8-10 ... by 8" diameter. Light weight ... ball bearings for effortless spin ... 30 inches from patient. Colorful ...
Medicine Products: